Goldman Sachs Upgrades Novo Nordisk A/S (NVO) to Buy
NVO Hot Sheet
Rating Summary:2 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Goldman Sachs upgrades Novo Nordisk A/S (NYSE: NVO) from Neutral to Buy, saying Levemir to benefit from Lantus safety fears after four studies were published showing the potential of increased cancer risk with Lantus. The firm said the negative press for Lantus will help sales of Novo's Levemir.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- JPMorgan Upgrades Illinois Tool Works (ITW) to Overweight
- Goldman Sachs Upgrades Northrop Grumman (NOC) to Neutral; Coming Back Onto Radar Screens
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
